Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shih Yea Sylvia, Faire, Bridget, Gane, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376942/
https://www.ncbi.nlm.nih.gov/pubmed/28408931
http://dx.doi.org/10.1155/2017/4895736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376942/
https://www.ncbi.nlm.nih.gov/pubmed/28408931
http://dx.doi.org/10.1155/2017/4895736

Ejemplares similares